Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Atea Pharmaceuticals, Inc.

AVIR ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$4.41

▲ +2.32%

Market Cap $353.70M · Vol 98.17K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$353.70M

Small Cap

Div Yield

N/A

EPS Growth

+9.28%

YoY

RSI (14)

48.38

Momentum

Beta

0.69

vs Market

52W High

$6.43

31.42% below

52W Low

$2.87

53.66% above

Volume

98.17K

Avg 126.63K

P/B

1.01

Price-to-book

ROE

-44.34%

Return on equity

Free Float

86.41%

Public shares

Shariah Compliance8 STANDARDS

✗ Atea Pharmaceuticals, Inc. (AVIR) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AVIR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+7.56%

-14.37%

-16.00%

-18.78%

YTD

+23.53%

+34.86%

+52.07%

-59.62%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-158,349,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-44.34%
ROA · ROIC	-42.19% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.01
P/FCF	N/A
EPS Growth	+9.28%
Outstanding Shares	80.20M

Technical Indicators

50-Day SMA	$4.90
200-Day SMA	$4.95
RSI (14)	48.38
Beta	0.69
52-Week High	$6.43
52-Week Low	$2.87

Volume Today	98.17K
Avg Daily Volume (30D)	126.63K
Relative Volume	0.78x
Volatility (10D)	53.42
Volatility (30D)	50.64
Free Float	86.41%

Analyst Consensus

BUY

Current Price $4.41

Mean Target $8.50

52W Low$2.87 52W High$6.43

Current

Target

$2.87 $6.43

Current Analyst target

+92.74% upside potential · 2 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00TZNCJ84

ISINUS04683R1068

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +2.27% ARGX.BR argenx SE +4.66% ARGX argenx SE +3.78% GMAB.CO Genmab A/S +3.80% GMAB Genmab A/S +4.05%

Company Profile

Atea Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Its product candidate pipeline includes the regimen of bemnifosbuvir and ruzasvir which has the potential to improve the current standard of care (SOC) for the treatment of patients with hepatitis C virus (HCV) infection and AT-587 which has the potential to be the first direct-acting antiviral (DAA) for the treatment of patients, particularly immunocompromised patients, with chronic hepatitis E virus (HEV) infection. The global HCV Phase III program it is conducting consists of two randomized, open-label studies: C-BEYOND which has clinical trial sites in the United States and Canada, and C-FORWARD which has clinical trial sites in countries outside of North America. AT-587 has demonstrated potent nanomolar antiviral activity against HEV in vitro.